title: [Cellular immune function influence on postoperative patients with hepatocellular carcinoma and the clinical effect of TILs treatment].
abstract: OBJECTIVE
  To investigate the cellular immune function influence on postoperative patients with hepatocellular carcinoma (HCC) and clinical effect of TILs, rIL-2 and cyclophosphamide treatment.
  
  
  METHODS
  Eight postoperative HCC patients were treated with TILs, rIL-2 and cyclophosphamide. Six patients were infused from the hepatic artery, and the other 2 infused from the portal vein.
  
  
  RESULTS
  The IL-2 NK activity, Tsubsets, CD4(+)/CD8(+) level in the peripheral blood of all patients increased and the IL-6, TNF level of most patients decreased (P > 0.05, P < 0.01). For 6 - 18 month follow-up after management, 6 patients with radical tumor resection showed no recurrence. One patient having palliative resection showed no remnant tumor enlargement. One patient with increased TNF level for 8 IU died from hepatic failure 8 months after chemotherapy.
  
  
  CONCLUSIONS
  The TILs, rIL-2 and cyclophosphamide treatment of postoperative HCC patients is effective in improving antitumorgenic immune function, preventing tumor recurrence, and restraining remnant tumor growth.
authors.affiliation: Department of Hepatic Bili Pancreatic Surgery, First University Hospital, West-China University of Medical Sciences, Chengdu 610041.
authors.forename: M
authors.initials: M
authors.lastname: Ba
authors.forename: S
authors.initials: S
authors.lastname: He
authors.forename: C
authors.initials: C
authors.lastname: Zhang
authors.forename: D
authors.initials: D
authors.lastname: Wei
authors.forename: Z
authors.initials: Z
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008297:Male; D008875:Middle Aged
chemical_list: D007376:Interleukin-2; D003520:Cyclophosphamide